Clinicopathological association and prognostic value of long non-coding RNA CASC9 in patients with cancer: A meta-analysis.
CASC9
cancer
long non-coding RNA
meta-analysis
prognosis
Journal
Experimental and therapeutic medicine
ISSN: 1792-0981
Titre abrégé: Exp Ther Med
Pays: Greece
ID NLM: 101531947
Informations de publication
Date de publication:
Oct 2020
Oct 2020
Historique:
received:
11
04
2020
accepted:
01
07
2020
entrez:
29
8
2020
pubmed:
29
8
2020
medline:
29
8
2020
Statut:
ppublish
Résumé
Several studies have reported a prognostic role of the long non-coding RNA (lncRNA) cancer susceptibility candidate 9 (CASC9) in various cancer types, but its clinical significance has remained inconclusive. The aim of the present meta-analysis was to evaluate the impact of CASC9 expression on the prognosis and clinicopathological features of patients with cancer patients. The PubMed, Embase, Cochrane Library and Web of Science databases were searched for relevant literature and eight studies, including 565 patients with cancer, were selected. The quality of these studies was appraised with the Newcastle-Ottawa Scale (NOS) and the association between CASC9 expression and prognosis or clinicopathological features was analyzed. Patients with high expression levels of CASC9 in their tumor tissues had a lower overall survival rate compared with those in the low CASC9 expression group (hazard ratio=2.25, 95% CI: 1.60-3.17, P<0.001). Furthermore, elevated CASC9 expression was significantly associated with deeper tumor invasion [odds ratio (OR)=2.66, 95% CI: 1.72-4.14, P<0.001], poor tumor differentiation (OR=2.44, 95% CI: 1.24-4.78, P=0.009), lymph node metastasis (OR=3.42, 95% CI: 1.98-5.92, P<0.001) and advanced clinical stage (OR=3.21, 95% CI: 2.21-4.66, P<0.001). In conclusion, CASC9 is a promising biomarker for predicting the prognosis of cancer patients and should be validated in the clinic.
Identifiants
pubmed: 32855732
doi: 10.3892/etm.2020.9096
pii: ETM-0-0-9096
pmc: PMC7444322
doi:
Types de publication
Journal Article
Langues
eng
Pagination
3823-3831Informations de copyright
Copyright: © Duan et al.
Références
Cell Death Dis. 2019 Jan 17;10(2):41
pubmed: 30674868
PLoS Med. 2009 Jul 21;6(7):e1000097
pubmed: 19621072
Int J Mol Sci. 2017 Jun 09;18(6):
pubmed: 28598379
Oncol Rep. 2019 Dec;42(6):2572-2582
pubmed: 31638237
J Hematol Oncol. 2014 Dec 10;7:90
pubmed: 25491133
Eur Rev Med Pharmacol Sci. 2016 Jul;20(14):3031-4
pubmed: 27460731
Mol Cancer. 2017 Aug 30;16(1):150
pubmed: 28854977
Eur Rev Med Pharmacol Sci. 2018 Jan;22(2):422-429
pubmed: 29424900
Nucleic Acids Res. 2013 Jan;41(Database issue):D48-55
pubmed: 23203987
Cancer Med. 2017 Mar;6(3):673-680
pubmed: 28220683
Biochem Biophys Res Commun. 2019 Aug 6;515(4):644-650
pubmed: 31178137
Trends Biochem Sci. 2016 Sep;41(9):761-772
pubmed: 27499234
J Clin Invest. 2016 Aug 1;126(8):2775-82
pubmed: 27479746
Cell Death Differ. 2018 Nov;25(11):1980-1995
pubmed: 29511340
Int J Genomics. 2013;2013:480534
pubmed: 24222893
Hepatology. 2018 Nov;68(5):1817-1832
pubmed: 29790588
Mod Pathol. 2013 Feb;26(2):155-65
pubmed: 22996375
Cell. 2013 Jul 3;154(1):26-46
pubmed: 23827673
Emerg Themes Epidemiol. 2008 Nov 17;5:23
pubmed: 19014686
J Cell Physiol. 2019 Jul;234(7):10800-10808
pubmed: 30537154
Biometrics. 1994 Dec;50(4):1088-101
pubmed: 7786990
Pathol Oncol Res. 2020 Jan;26(1):475-482
pubmed: 31642035
Eur J Epidemiol. 2010 Sep;25(9):603-5
pubmed: 20652370
Trials. 2007 Jun 07;8:16
pubmed: 17555582
Biometrics. 2000 Jun;56(2):455-63
pubmed: 10877304
Int J Mol Med. 2018 Nov;42(5):2801-2810
pubmed: 30106089
Int J Oncol. 2019 May;54(5):1651-1664
pubmed: 30896821
Oncogene. 2017 Oct 12;36(41):5661-5667
pubmed: 28604750
Biochim Biophys Acta. 2016 Jan;1859(1):147-54
pubmed: 26265144
J Exp Clin Cancer Res. 2019 Jun 11;38(1):249
pubmed: 31186036
RNA Biol. 2010 Sep-Oct;7(5):582-5
pubmed: 20930520
Int J Oncol. 2019 May;54(5):1665-1675
pubmed: 30816435
Med Sci (Paris). 2014 Aug-Sep;30(8-9):790-6
pubmed: 25174757
Front Genet. 2015 Apr 23;6:145
pubmed: 25954300
Cancer Med. 2016 Sep;5(9):2442-7
pubmed: 27431358
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Int J Oncol. 2019 Oct;55(4):860-878
pubmed: 31432149
Anticancer Res. 2015 Mar;35(3):1385-8
pubmed: 25750289
DNA Cell Biol. 2017 May;36(5):394-400
pubmed: 28398871